Dr. David Spigel: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?


Dr. David Spigel gives his view on more widespread availability of new mutation tests, provides his perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other lung cancer subtypes.


Subscribe to Sarah Cannon Cancer Center